The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...

The demand for GLP-1 medications is only increasing. As employees seek better health benefits, employers who act now will set ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...

ABC News medical correspondent Dr. Darien Sutton talks about GLP-1 drugs and access for teens and young adults in the U.S.

With its new serum, the medical grade skin care brand is targeting laxity, which many weight loss drug users experience.

Caution is needed until the harms are better understood Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising treatment for obesity and diabetes. Over the past few years, ...